A Phase 1 interventional study of Humanized anti-Factor Bb monoclonal antibody and Placebo in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Sanofi. Completed at 2 sites in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-22.
Sponsored by Sanofi · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Hemoglobinuria, Paroxysmal with a site in United States — 10 open to participants now, 16 under way, 4 of them phase 3. Hemoglobinuria, Paroxysmal · United States.
Among the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States, this one is the 27th largest by enrollment of the 54 interventional ones that give a count, is one of 5 that started in 2021, is one of 5 in phase 1, and was the 60th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →10 of the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Brazil, Colombia and 3 more countries
Ages 2–18
Alexion Pharmaceuticals, Inc. · Sites in United States, Australia, France and 4 more countries
Women only
Novartis Pharmaceuticals · Sites in United States
Ages 18–99
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages 0–75
International PNH Interest Group · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is above the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 53 across the 54 interventional studies, 75 across the 13 observational. Of the 50 that completed or were terminated, 26 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 68 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 1 study filed under Hemoglobinuria, Paroxysmal — fewer than ten, so there is no comparison to draw.
3 of the studies in Hemoglobinuria, Paroxysmal with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04432584Phase 3Hoffmann-La RocheA Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors | 2027-04-18 |
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
| NCT03520647National Heart, Lung, and Blood Institute (NHLBI)Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 68 studies in Hemoglobinuria, Paroxysmal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary objective
Screening: up to 56 days (Day -56 to Day -2). Treatment: 1 day (treatment on Day 1, study observation period from Day -1 to Day 3). Follow-up and end of study: 105 days after IMP administration (follow up visits from Day 5 to Day 78; End of study visit on Day 106). Total study duration for each participant: approximately 23 weeks.
Inclusion Criteria: Having given written prior to undertaking any study-related procedure Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply:
Any participant who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 1
Drug: Humanized anti-Factor Bb monoclonal antibody · Drug: Placebo
6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 2
Drug: Humanized anti-Factor Bb monoclonal antibody · Drug: Placebo
6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 3
Drug: Humanized anti-Factor Bb monoclonal antibody · Drug: Placebo
6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 4
Drug: Humanized anti-Factor Bb monoclonal antibody · Drug: Placebo
6 participants receiving SAR443809 and 2 receiving placebo, subcutaneous administration dose 5
Drug: Humanized anti-Factor Bb monoclonal antibody · Drug: Placebo
Optional: 6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 6
Drug: Humanized anti-Factor Bb monoclonal antibody · Drug: Placebo
Optional: 6 participants receiving SAR443809 and 2 receiving placebo, intravenous administration dose 7
Drug: Humanized anti-Factor Bb monoclonal antibody · Drug: Placebo
Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration
Also known as: SAR443809
Pharmaceutical form:Solution for injection-Route of administration:IV and SC routes of administration
Number of participants with adverse events (AEs)/treatment-emergent adverse events (TEAEs)
Time frame: Baseline up to 23 weeks
Incidence of potentially Clinical laboratory abnormalities
Time frame: Baseline up to 23 weeks
PK parameters of SAR443809 for IV and SC administrations: Maximum plasma concentration observed (Cmax
Time frame: Baseline up to 23 weeks
PK parameters of SAR443809 for IV and SC administrations: First time to reach Cmax (tmax
Time frame: Baseline up to 23 weeks
PK parameters of SAR443809 for IV and SC administrations: Area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to tlast (AUClast)
Time frame: Baseline up to 23 weeks
PK parameters of SAR443809 for IV and SC administrations: Area under the plasma concentration versus time curve extrapolated to infinity (AUC0-∞)
Time frame: Baseline up to 23 weeks
PK parameters of SAR443809 for IV and SC administrations: Terminal half-life associated with the terminal slope (λz) (t1/2z)
Time frame: Baseline up to 23 weeks
PK parameters of SAR443809 for IV and SC administrations: Time corresponding to the last concentration above the limit of quantification (Clast tlast)
Time frame: Baseline up to 23 weeks
PK parameters of SAR443809 for IV and SC administrations: total body clearance of a drug from the plasma calculated by dividing dose by AUC (CL)
Time frame: Baseline up to 23 weeks
PK parameters of SAR443809 for SC administrations: apparent total body clearance of the SC formulation (CL/F)
Time frame: Baseline up to 23 weeks
PK parameters of SAR443809 for IV and SC administrations: volume of distribution at steady-state (Vss)
Time frame: Baseline up to 23 weeks
PK parameters of SAR443809 for SC administrations: apparent volume of distribution at steady-state (Vss/F)
Time frame: Baseline up to 23 weeks
PK parameters of SAR443809 for SC administrations: absolute bioavailability (F)
Time frame: Baseline up to 23 weeks
Complement alternative pathway activity (Wieslab AP and alternative pathway hemolytic activity [AH50])
Ex vivo activity of the alternative pathway of complement in serum using the WIESLAB® Complement System Alternative Pathway kit and a hemolytic assay (AH50)
Time frame: Baseline up to 23 weeks
Complement classical pathway activity (Wieslab CP)
Ex vivo activity of the alternative pathway of complement in serum using the WIESLAB® Complement System Classical Pathway kit
Time frame: Baseline up to 23 weeks
Incidence of treatment -emergent Anti-SAR443809 antibodies
Time frame: Baseline up to 23 weeks
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
No publications or documents are linked to this record.
Ran from Oct 2021 to primary completion in May 2023, 18 months.
Of 19 phase 1 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's 18 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.